Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL25261563 | 0.96 | MCL1 (0.33) | MCL1EPHX1 | |
| SCHEMBL283516 | 0.80 | — | — | |
| SCHEMBL12282538 | 0.80 | RIPK1 (0.35) | MCL1 | |
| SCHEMBL18692589 | 0.77 | MCL1 (0.37) | MCL1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL17351504 | 0.77 | MCL1 (0.37) | MCL1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL16541488 | 0.75 | DPP4 (0.37) | MCL1KMT2AALDH1A1 | |
| SCHEMBL371371 | 0.75 | DPP4 (0.37) | MCL1KMT2AALDH1A1 | |
| SCHEMBL16866560 | 0.75 | MCL1 (0.35) | MCL1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL28505193 | 0.75 | MCL1 (0.32) | MCL1ALDH1A1 | |
| SCHEMBL24410355 | 0.73 | MCL1 (0.34) | MCL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| EP-4452966-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| CN-112236429-B | Heteroaryl compounds useful as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| EP-2885284-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | Respivert Limited (GB) | 2015-06-24 | — | — | EP | disclosed |
| US-20140057915-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-02-27 | — | — | US | disclosed |
| US-20140057915-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-02-27 | — | — | US | disclosed |
| US-20140057915-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-02-27 | — | — | US | disclosed |
| WO-2014027209-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-02-20 | — | — | WO | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | MAPK13, MAPK12, MAP3K13 | MCL1 461/4885EPHX1 1872/4885KMT2A 3281/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MCL1 2072/4885EPHX1 1327/4885KMT2A 2554/4885 |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP9 | MCL1 90/4885EPHX1 2234/4885KMT2A 2755/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | MCL1 56/4885EPHX1 3140/4885KMT2A 3281/4885 |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | MAPK13, MAPK11, MUC1 | MCL1 4578/4885EPHX1 1614/4885KMT2A 4069/4885 |
| US-20140057915-A1 | KINASE INHIBITORS | SYK, BTK, LYN | MCL1 1650/4885EPHX1 1315/4885KMT2A 2707/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | MCL1 10/4885EPHX1 1868/4885KMT2A 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.